The landscape of the clinical trial supply chain is changing throughout the world. Patient centricities and immune, cell and gene therapies are now the foundation of most treatments methods. The new EU regulations and Good Distribution Practices (GDP) guidelines, along with the industry’s need to decrease cost, reduce time to market and a harmonization of rules call for radical changes in the way trials are conducted.
- Exploring the value of home visits in clinical trials, the benefits gained by both the patient and the sponsor
- Marken Delivers Compassionate Use Dose of Emergency Medication to Critical Pediatric Patient
- Dissolving boundaries in worldwide clinical trial logistics
- MARKEN DELIVERS MEDICINE TO HELP SAVE A CHILD’S LIFE